Results 91 to 100 of about 1,349 (113)

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. [PDF]

Blood Adv
Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfò L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL.   +30 more
europepmc   +1 more source

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies. [PDF]

CPT Pharmacometrics Syst Pharmacol
Kemal CC, Zweers TJ, Krekels EHJ, Chatterjee MS.   +3 more
europepmc   +1 more source

Strongyloides stercoralis infection in a DLBCL patient treated with rituximab and BTK inhibitor: A case report and literature review. [PDF]

Medicine (Baltimore)
Liu W, Wang Z, Wu H, Zeng L, Cai N, Zhuang W, Guo J.   +6 more
europepmc   +1 more source

Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia. [PDF]

Sci Rep
Khan A, Ali SS, Zahid MA, Alshabrmi FM, Al-Zoubi RM, Shkoor M, Mohammmad A, Wei DQ, Agouni A.   +8 more
europepmc   +1 more source

BTK-Inhibition Enhances TLR-7-Mediated Interferon-Alpha Production in pDCs by Blocking the Inhibitory BDCA-2 Pathway. [PDF]

Eur J Immunol
Ceglarek L, Gerhards R, Boldrini V, Wichmann C, Peters A, Meinl E.   +5 more
europepmc   +1 more source

Altered PTPN13-β-catenin interaction by pathogenic mutations and involvement of this axis in B-cell receptor signalling. [PDF]

Sci Rep
Cabrera-Riofrío DA, Li H, García-Calvo C, Sánchez-Bernal C, Sánchez-Yagüe J, Dror Y, Buey RM, Hernández-Hernández Á.   +7 more
europepmc   +1 more source

Phosphorylation-Inducing Molecules for Regulating Dynamic Cellular Processes. [PDF]

J Am Chem Soc
Pergu R, Sreekanth V, Kokkonda P, Lai S, Tiwari PK, Singh S, Kawai J, Singha S, Tian W, Thimaradka V, Siriwongsup S, Tran K, Choudhary A.   +12 more
europepmc   +1 more source

Molecular insight on the role of the phosphoinositide PIP3 in regulating the protein kinases Akt, PDK1, and BTK. [PDF]

Biochem Soc Trans
Shaw AL, Burke JE.
europepmc   +1 more source

Identification of Bruton tyrosine kinase mutations in 12 Chinese patients with X‐linked agammaglobulinaemia by long PCR‐direct sequencing

International Journal of Immunogenetics, 2006
SummaryX‐linked agammaglobulinaemia (XLA) is an immunodeficiency caused by Bruton tyrosine kinase (BTK) gene mutations. The disease is characterized by recurrent bacterial infections and profound hypogammaglobulinemia with marked reduction or lack of mature B‐cells in the peripheral blood.
Lee, TL, Lee, BW, Fok, SFS, Jiang, L, Chen, T, Chan, KW, Lau, YL, Yang, X   +7 more
exaly   +7 more sources

X-linked agammaglobulinaemia: A novel single amino acid deletion in the PH region of Bruton's tyrosine kinase (Btk)

Immunology Letters, 1997
S. Pienaar, D.W. Beatty, B. Eley, H. Henderson   +3 more
exaly   +5 more sources